Ionis Pharmaceuticals, Inc. operates as a fully integrated, commercial-stage biotechnology company focused on RNA-targeted therapies for neurological, cardiometabolic, and rare genetic diseases. The company's core business model leverages its proprietary antisense oligonucleotide (ASO) technology platform to design drugs that bind to specific RNA sequences, thereby modulating gene expression and addressing the root causes of diseases. Ionis generates revenue through a diversified mix of direct product sales, licensing agreements, royalties, and collaborative research and development funding. Key revenue drivers include royalties from SPINRAZA (partnered with Biogen for spinal muscular atrophy), product sales from WAINUA (partnered with AstraZeneca for ATTRv-PN), and its independently launched drug TRYNGOLZA (for familial chylomicronemia syndrome). The company also has a robust pipeline of investigational medicines in late-stage development, such as donidalorsen. Geographically, Ionis is headquartered in the United States but reaches a global patient population through its strategic partnerships with major pharmaceutical companies like Biogen, AstraZeneca, Novartis, and Roche, which facilitate worldwide manufacturing and distribution. Its competitive position is anchored by its extensive intellectual property in antisense technology, its deep pipeline of genetic medicines, and its ongoing transition toward independently commercializing its wholly-owned assets.
